A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
Phase 4
Completed
- Conditions
- Interventions
- Drug: Risperidone 3 mgDrug: Paliperidone Palmitate 50 mg eq.Drug: Paliperidone Palmitate 75 mg eq.Drug: Paliperidone Palmitate 100 mg eq.Drug: Paliperidone Palmitate 150 mg eq.Drug: Paliperidone Palmitate 175 mg eq.Drug: Paliperidone Palmitate 263 mg eq.Drug: Paliperidone Palmitate 350 mg eq.Drug: Paliperidone Palmitate 525 mg eq.
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 93
- Registration Number
- NCT04940039
- Locations
- 🇷🇼
CARAES Ndera Neuro-Psychiatric Hospital, Kigali, Rwanda
🇷🇼Kibuye Referral Hospital, Kibuye, Rwanda
🇷🇼University Teaching Hospital of Kigali, Kigali, Rwanda
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 676
- Registration Number
- NCT04338321
- Locations
- 🇩🇪
Universitatsklinikum Jena, Jena, Germany
🇵🇱Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk, Poland
🇵🇹Fund. Champalimaud, Lisboa, Portugal
A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 29
- Registration Number
- NCT03947814
- Locations
- 🇩🇪
APEX GmbH, Munchen, Germany
🇩🇪CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Janssen-Cilag International NV
- Registration Number
- NCT03852160
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 880
- Registration Number
- NCT03818035
- Locations
- 🇩🇪
MVZ Dermatologisches Zentrum Bonn GmbH, Bonn, Germany
🇩🇪Universitatsklinikum Dusseldorf, Düsseldorf, Germany
🇫🇷Hopital Prive d'Antony, Antony, France
A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 42
- Registration Number
- NCT03816631
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪APEX GmbH, Munchen, Germany
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 225
- Registration Number
- NCT03809325
- Locations
- 🇫🇷
Centre Médico Psychologique De Courbevoie, Asnieres Sur Seine, France
🇬🇧West London Mental Health Trust, London, United Kingdom
🇫🇷Cabinet medical, Dax, France
A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 18
- Registration Number
- NCT03768609
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Determine the Epidemiology and Evaluate the Burden of Disease in Respiratory Syncytial Virus/Human Metapneumovirus and Influenza A Infected Hospitalized Participants (Adults and Children)
Completed
- Conditions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 118
- Registration Number
- NCT03574532
- Locations
- 🇩🇪
Universitätsklinikum Würzburg, Würzburg, Germany
🇪🇸Hosp. Univ. de La Princesa, Madrid, Spain
A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 14
- Registration Number
- NCT03547024
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
© Copyright 2024. All Rights Reserved by MedPath